EUVIMEDAvasta EUVIMED
Crossref

High-Throughput In Vivo Screening Identifies Structural Factors Driving mRNA Lipid Nanoparticle Delivery to the Brain

Emily L Han iD, Dongyoon Kim iD, Amanda M Murray iD, Kaitlin Mrksich iD, Alex G Hamilton iD, Sophia Tang iD, Soyeon Yoo iD, Audrey T Zhu, Elaine R Tong, Rohan Palanki iD, Michelle L Hall, Sean K Bedingfield and 1 more

ACS Nano · 2026-02-03 · 20 (4) · 3807-3820

DOI: 10.1021/acsnano.5c19138 ↗

At a glance

Journal article in ACS Nano, published online on 2026-01-20. Written by Emily L Han and 12 co-authors. Institution: Department of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States. Major MEDLINE topics: Lipids, RNA, Messenger, Nanoparticles, Brain. Cited 9 times so far (Crossref); 52 references. Funded by: Burroughs Wellcome Fund, Eli Lilly and Company, National Science Foundation.

AbstraktSubjectsBibliograafilised andmedCiteRelated studies

Abstract (original language)

Achieving systemic nonviral delivery of large nucleic acids such as mRNA to the brain is challenging due to high off-target delivery and the blood-brain barrier (BBB), a cellular barrier which prevents most nucleic acids in circulation from entering the brain. Ionizable lipid nanoparticles (LNPs) are a promising class of nanocarriers to facilitate the delivery of mRNA, as their highly modular nature enables fine-tuning of the LNP formulation for targeted delivery applications. In this work, we explore the role of ionizable lipid chemical structure and lipid molar ratios within the LNP formulation on mRNA delivery to and transfection of the brain. We utilize a high-throughput in vivo screening approach based on mRNA barcoding to study a large library of LNPs made with systematically varied ionizable lipid structures, amounts of ionizable lipid, and amounts of lipid-polyethylene glycol (PEG). We find that ionizable lipids with longer tail structures and linear amine cores can facilitate mRNA delivery to the mouse brain, and ultimately identify a specific ionizable lipid, C14-306, that facilitates brain transfection coupled with reduced liver transfection compared to an FDA-approved benchmark formulation. Furthermore, the lead LNP formulated with C14-306 is able to increase neuronal transfection and facilitate Cre-mediated recombination in the brain. Finally, safety analyses demonstrate that the lead LNP does not induce BBB leakage, increases in serum inflammatory cytokine levels, or increases in serum liver enzyme levels. Overall, our work highlights the utility of molecular barcoding for high-throughput screening of LNPs for delivery to the brain and suggests several design principles to guide the engineering of next-generation brain-tropic LNPs.

Subjects

MeSH terms (MEDLINE)

LipidsRNA, MessengerNanoparticlesBrainHigh-Throughput Screening AssaysAnimalsMiceBlood-Brain BarrierTransfectionPolyethylene GlycolsMice, Inbred C57BLLiposomes

Author keywords

braindrug deliverylipid nanoparticlesmRNAnanomedicine

Substances

LipidsRNA, MessengerLipid NanoparticlesPolyethylene GlycolsLiposomes

Authors and institutions

  • Department of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States.
  • Lilly Institute of Genetic Medicine, Eli Lilly & Company, Boston, Massachusetts 02210, United States.
  • Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States.
  • Cardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States.
  • Institute for Regenerative Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States.
  • Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States.

ORCID profiles: Emily L Han, Dongyoon Kim, Amanda M Murray, Kaitlin Mrksich, Alex G Hamilton, Sophia Tang, Soyeon Yoo, Rohan Palanki, Michael J Mitchell

Funding

  • Burroughs Wellcome Fund
  • Eli Lilly and Company
  • National Science Foundation

Cite

APA

Han, E. L., Kim, D., Murray, A. M., Mrksich, K., Hamilton, A. G., Tang, S., Yoo, S., Zhu, A. T., Tong, E. R., Palanki, R., Hall, M. L., Bedingfield, S. K., & Mitchell, M. J. (2026). High-Throughput In Vivo Screening Identifies Structural Factors Driving mRNA Lipid Nanoparticle Delivery to the Brain. ACS Nano, 20(4), 3807-3820. https://doi.org/10.1021/acsnano.5c19138

Vancouver

Han EL, Kim D, Murray AM, Mrksich K, Hamilton AG, Tang S, et al. High-Throughput In Vivo Screening Identifies Structural Factors Driving mRNA Lipid Nanoparticle Delivery to the Brain. ACS Nano. 2026;20(4):3807-3820. doi:10.1021/acsnano.5c19138

BibTeX
@article{Han2026,
  author = {Han, Emily L and Kim, Dongyoon and Murray, Amanda M and Mrksich, Kaitlin and Hamilton, Alex G and Tang, Sophia and Yoo, Soyeon and Zhu, Audrey T and Tong, Elaine R and Palanki, Rohan and Hall, Michelle L and Bedingfield, Sean K and Mitchell, Michael J},
  title = {High-Throughput In Vivo Screening Identifies Structural Factors Driving mRNA Lipid Nanoparticle Delivery to the Brain},
  journal = {ACS Nano},
  year = {2026},
  volume = {20},
  number = {4},
  pages = {3807--3820},
  doi = {10.1021/acsnano.5c19138}
}
Start for free →